Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference
Surrozen, a biotechnology firm listed on NASDAQ under the ticker SRZN, announced that CEO Craig Parker will speak at the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 22 at 10:00 a.m. ET. The event will be accessible via a live webcast on the Surrozen website, with an archived replay available later.
Surrozen focuses on developing drug candidates that selectively modulate the Wnt pathway, which is crucial for organ development and regeneration. Their proprietary technology aims to address various degenerative diseases and tissue injuries.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 10:00 a.m. ET on Monday, November 22. Interested parties may access the live webcast via the Investors section of the Surrozen website at www.surrozen.com. A replay of the webcast will be archived on the website.
About Wnt Signaling
Wnt signaling plays key roles in the control of development, homeostasis, and regeneration of many essential organs and tissues, including liver, intestine, lung, kidney, retina, central nervous system, cochlea, bone, and others. Modulation of Wnt signaling pathways has potential for treatment of degenerative diseases and tissue injuries. Surrozen’s platform and proprietary technologies have the potential to overcome the limitations in pursuing the Wnt pathway as a therapeutic strategy.
About Surrozen
Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. For more information, please visit surrozen.com.
Media Contact:
Ian Stone, Managing Director
CanaleComm
Tel.: (619) 518-3518
Email: ian.stone@canalecomm.com
Investor Contact:
Email: Investorinfo@surrozen.com
FAQ
When is Surrozen's CEO Craig Parker speaking at the Piper Sandler conference?
How can I access the Surrozen conference webcast?
What is the focus of Surrozen's drug development?
What diseases does Surrozen's technology aim to address?
Where can I find more information about Surrozen?
